Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
about
BRCAness: finding the Achilles heel in ovarian cancerChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingPARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesNovel therapeutic strategies for patients with triple-negative breast cancerA Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer ModelSingle cell resolution in vivo imaging of DNA damage following PARP inhibitionSynthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.Investigational agents in development for the treatment of ovarian cancerA high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancerCurrent and future systemic treatment options in metastatic pancreatic cancer.ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.Treating breast cancer in the 21st century: emerging biological therapiesThe promise and peril of chemical probes.Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.Familial breast cancer - targeted therapy in secondary and tertiary preventionPhase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Advances in small-molecule drug discovery for triple-negative breast cancer.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?Ovarian cancer: in search of better marker systems based on DNA repair defectsPhase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.Population and target considerations for triple-negative breast cancer clinical trials.SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.Synthetic genetic targeting of genome instability in cancer.A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesStructural Implications for Selective Targeting of PARPs.DNA repair in cancer: emerging targets for personalized therapy.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Novel targeted agents for the treatment of advanced breast cancer.Targeted therapy for triple-negative breast cancer: where are we?Cancer treatment according to BRCA1 and BRCA2 mutations.PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.PARP inhibitors in cancer therapy: an update.A review of iniparib in ovarian cancer.
P2860
Q24630872-6B688837-C87F-4867-B168-936561531030Q26863501-23995542-B385-4691-ACA3-44219CA976A7Q27027503-C5FB1A5A-7381-42EA-A9F3-AB4F7E943268Q28067436-E588282A-5D90-44F0-9647-B8A4F3719135Q28550119-F5502D73-BB09-44C6-96CE-1AA6934A6498Q30650918-34DEE245-3962-42C4-B00E-4B21F2FD6580Q33607384-4611384F-9462-4944-99CE-0BE65B762325Q33874621-949622B2-881B-4BB3-A752-69FB05A70FA1Q33906319-294AE794-B2AB-455D-AD8F-4879DC24D654Q33920800-CD63892B-D709-40FF-84B3-61DBCB6FD9B1Q33946208-F2D28E09-3787-48C4-AF30-BFCB91DC1E53Q33948033-06C625EE-7F24-48BF-9E48-34A15895037EQ34249365-21211F23-5DB5-40F9-AED0-4584EB27B61CQ34326536-908CE062-6276-4971-B124-31A7531D4EAFQ34486195-3C30D6FB-0817-40BC-AED8-14C5A56AE432Q34520145-9FD392D2-5B0B-4A9F-8B0B-2568845AC6B9Q35399626-DDCBA401-CA78-4D54-A23F-ED7F43158814Q35671356-588F2584-4312-46C4-A59E-901467DF324DQ35818491-DBF6F340-1095-4C25-B606-32C881FCE1FBQ35895214-2ED783E1-23F1-40AC-BEA8-31C8FB73825CQ36280791-F7E91FE5-9486-416F-AF6E-A876B56483DFQ36490203-207EBD20-E8A8-42EE-B196-96E4CD77FD2CQ36589947-27D704EC-D5AF-4B00-A97B-F311E9127993Q36908133-99829DFA-8232-4318-98D5-3AC9AB574AE3Q36913813-80644C1B-D544-4B9A-84FE-EB874343D469Q36914317-CFA2F8DC-A2F8-488D-9141-66ABDA570422Q37148642-F755D8A2-3629-46BA-81B8-CEAD623512CFQ37220528-E7F4F460-31F4-4EAF-B0AA-AA98CF7C9B95Q37226478-89DCBE22-604C-4BB8-9C8E-B231B3FC6EAEQ37228176-D31E88C3-54BA-438B-84E8-5458828366C1Q37269217-A088A761-3D81-4C83-8554-99E8C80DDCA3Q37405386-DE2AA03E-3FA3-4139-B8BE-8EAD7B1BDA93Q37600799-6BF69296-B468-44D1-BA43-942924FBE4FFQ37607283-67B98FC9-4B07-47CB-964A-30BBF42C63B9Q38008723-28DBD16D-7952-4293-9830-AEAD0566B4E4Q38009760-79AEC743-CA8F-43E3-87C7-8E192ABBDCD6Q38028798-2DA33829-5EF5-400D-988D-B453DFBC9D7FQ38029726-8286FE03-9104-45DB-8481-13F367D6F720Q38078993-74D47B66-8231-48EA-8C95-F6DE24F23347Q38080153-16E63996-433D-465F-823B-E6CE58CD6030
P2860
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@ast
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@en
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@nl
type
label
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@ast
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@en
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@nl
prefLabel
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@ast
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@en
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@nl
P2093
P1476
Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.
@en
P2093
Alexander R Shoemaker
Allison J Xu
Bruce W Surber
Cherrie K Donawho
Damien B Ready
David X Maag
Eric F Johnson
Joann P Palma
John E Harlan
Larry R Solomon
P304
P356
10.1158/1078-0432.CCR-11-1973
P407
P577
2011-11-29T00:00:00Z